Antidepressants for smoking cessation.

Area of Science:

• Pharmacology and Addiction Medicine
• Evidence-Based Medicine
• Clinical Trial Analysis

Background:

• Antidepressants may help smoking cessation by alleviating nicotine withdrawal-induced depressive symptoms.
• Specific antidepressant mechanisms may target neural pathways involved in nicotine addiction.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of antidepressant medications for long-term smoking cessation.
• To synthesize evidence from randomized controlled trials (RCTs) comparing antidepressants with placebo or other cessation aids.

Main Methods:

• Systematic review and meta-analysis of 115 RCTs (minimum 6-month follow-up for efficacy).
• Data extraction and risk of bias assessment using Cochrane methods; GRADE for certainty of evidence.
• Primary outcome: smoking cessation rates; secondary outcomes: adverse events (AEs), serious adverse events (SAEs), and treatment discontinuation.

Main Results:

• High-certainty evidence shows bupropion increases long-term smoking cessation (RR 1.64).
• Bupropion increases trial dropouts due to AEs (RR 1.37) and psychiatric AEs (RR 1.25).
• Nortriptyline shows some evidence of aiding cessation (RR 2.03); bupropion is less effective than varenicline.

Conclusions:

• Bupropion is effective for smoking cessation but associated with increased AEs and discontinuations.
• Nortriptyline also appears beneficial; bupropion's efficacy is comparable to NRT but lower than varenicline.
• Limited evidence for other antidepressants; further research on safety and tolerability is warranted.